RxDoctor Payments Data

Claudia Porter-Lawrence, APRN

Psychiatric/Mental Health · Stuart, FLNPI 1104467877

Payments from drug & device makers

$2,723in general payments, 2019–2025

Across 134 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$647
  • Teva Pharmaceuticals USA, Inc.$604
  • AbbVie$309
  • Alkermes, Inc.$306
  • Otsuka America Pharmaceutical, Inc.$282
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$214
  • plus $362 from 4 others

What the payments were for

  • Food & beverage$2,61896%
  • Education$1044%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,723 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$20,606
Medicare patients
19
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate146$366,909
AustedoDeutetrabenazine20$172,154
Abilify MaintenaAripiprazole26$55,281
LybalviOlanzapine/Samidorphan Malate29$45,771
VraylarCariprazine Hcl15$20,527
RexultiBrexpiprazole13$19,235
Paliperidone ErPaliperidone36$6,340
Olanzapine161$5,164
Haloperidol Decanoate107$4,436
Clozapine83$4,405
Fluphenazine Decanoate33$3,935
Oxcarbazepine103$3,565
Fluphenazine Hcl73$3,347
Haloperidol80$2,607
Benztropine Mesylate278$2,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$647$366,909146 claims
Teva Pharmaceuticals USA, Inc.Austedo$604$172,15420 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$282$74,51739 claims
Alkermes, Inc.Lybalvi$306$45,77129 claims
AbbVieVraylar$309$20,52715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →